BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29424433)

  • 1. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
    Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
    Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient with primary Sjogren's syndrome, cystic lung disease, and MALT lymphoma treated successfully with rituximab: a case-based review.
    Wise LM; Arkfeld DG
    Clin Rheumatol; 2020 Apr; 39(4):1357-1362. PubMed ID: 31863212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
    Yamasaki M; Funaishi K; Muta T; Matsumoto N; Taniwaki M; Hattori N
    QJM; 2019 Oct; 112(10):807-808. PubMed ID: 30895318
    [No Abstract]   [Full Text] [Related]  

  • 5. Minimal change disease: an unusual presentation of marginal zone MALT lymphoma.
    Inayat F; Law JK; Myers-Gurevitch PM; Seshan SV; Perlman AS
    Clin Nephrol; 2016 Mar; 85(3):184-8. PubMed ID: 26636329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
    Cencini E; Fabbri A; Schiattone L; Bocchia M
    Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
    Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma.
    Pijpe J; van Imhoff GW; Vissink A; van der Wal JE; Kluin PM; Spijkervet FK; Kallenberg CG; Bootsma H
    Ann Rheum Dis; 2005 Jun; 64(6):958-60. PubMed ID: 15576414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhemolysis associated with marginal zone lymphoma.
    Yan M; Callum J; Lin Y
    Leuk Lymphoma; 2015 Mar; 56(3):829-31. PubMed ID: 24991717
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
    Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
    Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
    Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FcRL4
    Haacke EA; Bootsma H; Spijkervet FKL; Visser A; Vissink A; Kluin PM; Kroese FGM
    J Autoimmun; 2017 Jul; 81():90-98. PubMed ID: 28390747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of refractory MALT lymphoma by lenalidomide plus bendamustine: A case report.
    Zhou Z; Wu P; Wang F; Tao H; Chen Y; Gao J; Chen D; Jia Y
    Medicine (Baltimore); 2022 Mar; 101(9):e28938. PubMed ID: 35244050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gallium-67 scintigraphic findings in a patient with breast lymphoma complicated with Sjögren syndrome.
    Yoshimura M; Koizumi K; Satani K; Kakizaki D; Kawanishi Y; Ohyashiki K; Abe K
    Ann Nucl Med; 2000 Jun; 14(3):227-9. PubMed ID: 10921490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma].
    Vasil'ev VI; Kokosadze NV; Logvinenko OA; Nikitin EA; Mitrikov BV; Rodionova EB; Varlamova EIu
    Ter Arkh; 2008; 80(5):76-9. PubMed ID: 18590121
    [No Abstract]   [Full Text] [Related]  

  • 17. [Association between thymic MALT lymphoma and Sjögren's syndrome].
    Giroux Leprieur E; Antoine M; Gounant V; Copie-Bergman C; Lavole A; Milleron B
    Rev Pneumol Clin; 2009 Apr; 65(2):108-12. PubMed ID: 19375051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome.
    Verstappen GM; Moerman RV; van Nimwegen JF; van Ginkel MS; Bijzet J; Mossel E; Vissink A; Hazenberg BPC; Arends S; Kroese FGM; Bootsma H
    Rheumatology (Oxford); 2018 Oct; 57(10):1812-1821. PubMed ID: 29982712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience.
    Logothetis CN; Horvat NP; Kurian T; Bello C; Chavez J; Isenalumhe L; Shah B; Sokol L; Saeed H; Pinilla J; Gaballa S
    Oncol Res; 2024; 32(6):1031-1036. PubMed ID: 38827319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
    Castelli R; Bergamaschini L; Deliliers GL
    Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.